Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6645-8. doi: 10.1016/j.bmcl.2009.10.012. Epub 2009 Oct 8.

(4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors.

Author information

1
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, Saitama-shi, Saitama 331-9530, Japan. tomomichi.chonan@po.rd.taisho.co.jp

Abstract

Acetyl-CoA carboxylases (ACCs), the rate limiting enzymes in de novo lipid synthesis, play important roles in modulating energy metabolism. The inhibition of ACC has demonstrated promising therapeutic potential for treating obesity and type 2 diabetes mellitus in transgenic mice and preclinical animal models. We describe herein the synthesis and structure-activity relationships of a series of disubstituted (4-piperidinyl)-piperazine derivatives as a new platform for ACC1/2 non-selective inhibitors.

PMID:
19853443
DOI:
10.1016/j.bmcl.2009.10.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center